<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03799978</url>
  </required_header>
  <id_info>
    <org_study_id>ID-078-113</org_study_id>
    <nct_id>NCT03799978</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Two Way Crossover Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, randomized, two way crossover study to investigate the
      food effect on the pharmacokinetics of ACT-541468 in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2019</start_date>
  <completion_date type="Actual">March 18, 2019</completion_date>
  <primary_completion_date type="Actual">March 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two way crossover</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic endpoint: AUC0-24</measure>
    <time_frame>Multiple timepoints; duration: up to 48 hours in each treatment period</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time zero to 24 h</description>
  </primary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic endpoint: AUC0-inf</measure>
    <time_frame>Multiple timepoints; duration: up to 48 hours in each treatment period</time_frame>
    <description>AUC from time zero to infinity</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic endpoint: Cmax</measure>
    <time_frame>Multiple timepoints; duration: up to 48 hours in each treatment period</time_frame>
    <description>Maximum plasma concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic endpoint: tmax</measure>
    <time_frame>Multiple timepoints; duration: up to 48 hours in each treatment period</time_frame>
    <description>Time to reach maximum plasma concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic endpoint: tÂ½</measure>
    <time_frame>Multiple timepoints; duration: up to 48 hours in each treatment period</time_frame>
    <description>Terminal elimination half-life</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>From study treatment administration up to EOT; duration: up to 48 hours in each treatment period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serious treatment-emergent adverse events</measure>
    <time_frame>From study treatment administration up to EOT; duration: up to 48 hours in each treatment period</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A: ACT-541468 50 mg under fasted conditions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose administered on Day 1 under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: ACT-541468 50 mg under fed conditions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose administered on Day 1 administered after food intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-541468</intervention_name>
    <description>ACT-541468 50 mg film-coated tablets</description>
    <arm_group_label>Treatment A: ACT-541468 50 mg under fasted conditions</arm_group_label>
    <arm_group_label>Treatment B: ACT-541468 50 mg under fed conditions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure

          -  Healthy male subjects aged between 18 and 45 years (inclusive) at Screening

          -  Body mass index (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at Screening

          -  No clinically relevant findings on the physical examination at Screening

        Exclusion Criteria:

          -  History of major medical or surgical disorders, which, in the opinion of the
             investigator, are likely to interfere with the absorption, distribution, metabolism,
             or excretion of the study treatments (appendectomy and herniotomy allowed,
             cholecystectomy not allowed)

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol

          -  Modified Swiss Narcolepsy Scale total score &lt; 0 at screening or history of narcolepsy
             or cataplexy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CEPHA s.r.o.</name>
      <address>
        <city>Pilsen</city>
        <zip>323 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2019</study_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

